Activity of albendazole and essential oils of peppermint (Mentha piperita) and chamomile (Matricaria chamomilla) against Anisakis type I
Keywords:
Anisakis, Albendazole, Chamomile, Mentha, PCR-RFLPAbstract
Aim: We have studied the possible synergistic activity of the essential oils of Mentha piperita and Matricaria chamomile against Anisakis type I.
Materials and methods: the larvicidal activity of the mixture of essential oils was tested in vitro and in vivo, using as a reference the drug Albendazole and effectiveness measured through a statistical model.
Results: The in vitro and in vivo experiments both evidenced that the larvicidal activity of essential oils, was higher than the Albendazole activity. In the in vitro assay, at concentrations of 250 and 187.5 μg/ml, the mortality was 100% with the mixture of essential oils while albendazole was ineffective at the concentrations studied. In the in vivo assay, the mixture of essential oils, was significantly more effective in the reduction of numbers of lesions with rats in comparison to albendazole treatments and control. Albendazole did not significantly reduce the percentage of lesions caused by larvae vs. control.
Conclusion: Considering the results, we have come to the conclusion that the mixture of peppermint essential oils and chamomile could be used in the treatment/prophylaxis of human Anisakis.
Downloads
References
Muraoka A, Suehiro I, Fujii M, Nagata K, Kusunoki H, Kumon Y, et al. Acute gastric anisakiasis: 28 cases during the last 10 years. Dig Dis Sci. 1996; 41(12):2362-2365.
Filauro M, Rollandi GA, Cassola G, Quilici P, Angelini G, Belli F, et al. Gastrointestinal bleeding due to suspected anisakiasis: challenging differential diagnosis for a rare disease. Updates Surg. 2011; 63(3):213-217.
Hierro I, Valero A, Perez P, Gonzalez P, Cabo MM, Montilla MP, et al. Action of different monoterpenic compounds against Anisakis simplex s.l. L3 larvae. Phytomed. 2004; 11(1):77-82.
Navarro-Moll MC, Romero MC, Montilla MP, Valero A. In vitro and in vivo activity of three sesquiterpenes against L3 larvae of Anisakis type I. Exp Parasitol. 2011; 127(2):405-408.
Romero M, Valero López A. Actividad in vivo del mentol frente a larvas L3 de Anisakis tipo I. Ars Pharm. 2010; 51(3):841-846.
Romero MC, Valero A, Martin-Sanchez J, Navarro-Moll MC. Activity of Matricaria chamomilla essential oil against anisakiasis. Phytomed. 2012; 19(6):520-523.
Real Farmacopea Española. Agencia Española del Medicamento. Ministerio de Sanidad y Consumo. 2005.
Moore DA, Girdwood RW, Chiodini PL. Treatment of anisakiasis with albendazole. Lancet. 2002; 360(9326):54.
Ruckebusch Y. Données numériques et miscellanées. Physiologie pharmacologie thérapeutique animales. París: Maloine S.M.; 1977.
Zúñiga JM, Orellana JM, Tur JA. Ciencia y Tecnología del Animal de Laboratorio. Madrid: Universidad de Alcalá de Henares; 2011.
Zhu X, Gasser RB, Podolska M, Chilton NB. Characterisation of anisakid nematodes with zoonotic potential by nuclear ribosomal DNA sequences. Int J Parasitol. 1998; 28(12):1911-1921.
D’Amelio S, Mathiopoulos KD, Santos CP, Pugachev ON, Webb SC, Picanco M, et al. Genetic markers in ribosomal DNA for the identification of members of the genus Anisakis (Nematoda: ascaridoidea) defined by polymerase-chain-reaction-based restriction fragment length polymorphism. Int J Parasitol. 2000; 30(2):223-226.
Pontone S, Leonetti G, Guaitoli E, Mocini R, Manfredelli S, Catania A, et al. Should the host reaction to anisakiasis influence the treatment? Different clinical presentations in two cases. Rev Esp Enferm Dig. 2012; 104(11):607-610.
Arias-Díaz J, Zuloaga J, Vara E, Balibrea J, Balibrea JL. Efficacy of albendazole against Anisakis simplex larvae in vitro. Dig Liver Dis. 2006; 38(1):24-26.
Flórez J. Fármacos antiparasitarios: protozoos y helmintos. En: Flórez J, editor. Farmacología humana. Barcelona: Masson; 2003. p. 1361-1390.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).